Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

Sponsor
Azidus Brasil
Study ID
NCT06817096
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nitazoxanide 600Mg Oral Tablet / placebo oral tablet — DRUG
    1 tablet every 12 hours

Study Details

2\. Participants will: * Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. * Visit the clinic on the 7th day of treatment for a check-up and safety tests. * Keep a diary of their symptoms and other medications used

Key Dates

First listed
Feb 10, 2025
Start date
Feb 28, 2025
Status verified
Feb 2025
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
340 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: placebo
    take placebo orally, twice daily for 7 days.
  • Experimental: nitazoxanide
    take nitazoxanide 600 mg orally, twice daily for 7 days

Primary Outcome Measure

Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of COVID-19 [ Time Frame: From enrollment to the end of treatment will last up to 60 days ]

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies